Signatur Biosciences

Signatur Biosciences develops decentralised precision diagnostics that translate multi-gene expression signatures into PCR-based assays runnable in local hospital laboratories, with a first product for early breast cancer prognosis to guide chemotherapy decisions, cutting turnaround from weeks in a centralised laboratory to days at a fraction of the cost. The company is London-based and remains active in the YC directory; clinical validation data have not been published in a primary source found at the time of checking.